← Back to list
Macular/Foveal Translocation (CPB 0409, reviewed 2026-07-06)
Effective date
Not stated in the notice
Identified
Aug 17, 2026
Summary
Aetna considers macular/foveal translocation experimental, investigational, or unproven for age-related macular degeneration (AMD) and for all other indications, because its safety and effectiveness have not been established in the medical literature. The policy lists no specific CPT or HCPCS codes for this procedure. It lists ICD-10 codes H35.051 to H35.059 (retinal neovascularization) and H35.30 to H35.3293 (age-related macular degeneration) as not covered for the indications in the bulletin, and states that the list is not all inclusive.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.
Get Aetna alertsPolicy Monitoring is free. No card required.
What to do
Action · 2 steps
01Do not expect coverage for macular/foveal translocation for AMD or any other indication, because Aetna considers it experimental, investigational, or unproven.
02Billing team: before scheduling or billing this procedure for retinal neovascularization or AMD, confirm the diagnosis codes against the ICD-10 ranges the policy lists as not covered (H35.051 to H35.059 and H35.30 to H35.3293).
Codes mentioned
H35.051H35.059H35.30H35.3293
Original notice
Macular/Foveal Translocation (CPB 0409, reviewed 2026-07-06)
aetna.com · Always check the source before changing claims.
Related changes
See all Aetna changes →Revakinagene Taroretcel-lwey (Encelto) (CPB 1079, reviewed 2026-10-05)MediumEffective Jul 16, 2025 · Medical PolicyLaser Photocoagulation of Drusen (CPB 0609, reviewed 2026-09-03)MediumNo effective date · Medical PolicyBrachytherapy (CPB 0371, reviewed 2026-05-20)MediumNo effective date · Medical PolicyVerteporfin (Visudyne) Photodynamic Therapy (CPB 0594, reviewed 2026-04-24)MediumNo effective date · Medical PolicyBrowse every Aetna change in the policy list